Brandon Abbs, PhD

ENHANCE Trial: Adherence to Current Antipsychotic and Adjunctive Pimavanserin in Patients With Schizophrenia and Inadequate Response to Antipsychotic Treatment

Up to 70% of individuals with schizophrenia experience inadequate response to antipsychotic treatment potentially due to insufficient exposure due to nonadherence or to medication ineffec...

Brandon Abbs , PhD;

Mona Darwish , PhD;

Dragana Bugarski-Kirola , MD, MBA, MSc;

Yuan Liu , MSc;

Srdjan Stankovic , MD, MSPH;

10/27/2020

ADVANCE: Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Negative Symptoms of Schizophrenia

Pimavanserin is a selective, 5-hydroxytryptamine (5-HT)2A receptor inverse agonist/antagonist with lower activity at 5-HT2C receptors. Previous studies have shown beneficial effects of ad...

Dragana Bugarski-Kirola , MD, MBA, MSc;

Srdjan Stankovic , MD, MSPH;

Celso Arango , MD, PhD;

Henry Nasrallah , MD;

I-Yuan Liu , MSc;

Brandon Abbs , PhD;

Maurizio Fava , MD, PhD;

10/08/2020